跳至主要内容
临床试验/NCT00130078
NCT00130078Unknown3 期

Randomized Controlled Trial of SAVVY and HIV in Nigeria

Biosyn2 个研究点 分布在 1 个国家目标入组 2,142 人开始时间: 2004年9月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
发起方
入组人数
2,142
试验地点
2
主要终点
Combined incidence of HIV-1 and HIV-2

研究概览

简要总结

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

详细描述

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 18 to 35 year old women
  • HIV negative
  • More than one sexual partner in past 3 months
  • Average 3 coital acts per week
  • Willing to use vaginal gel and condoms for 12 months

排除标准

  • HIV positive

结局指标

主要结局

Combined incidence of HIV-1 and HIV-2

次要结局

未报告次要终点

研究者

发起方
Biosyn
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验